| Title : Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems - Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| Author(s) : Yokoyama Y , Estok TM , Wild R |
| Ref : Mol Cancer Ther , 21 :1561 , 2022 |
| Abstract : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| ESTHER : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| PubMedSearch : Yokoyama_2022_Mol.Cancer.Ther_21_1561 |
| PubMedID: 35930753 |
Yokoyama Y, Estok TM, Wild R (2022)
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems
Mol Cancer Ther
21 :1561
Yokoyama Y, Estok TM, Wild R (2022)
Mol Cancer Ther
21 :1561